A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.
- Park, S.
- Chapuis, N.
- Saint-Marcoux, Franck
- Recher, C.
- Prebet, T.
- Chevallier, P.
- Cahn, J.-Y.
- Leguay, T.
- Bories, P.
- Witz, F.
- Lamy, T.
- Mayeux, P.
- Lacombe, C.
- Demur, C.
- Tamburini, J.
- Merlat, A.
- Delepine, R.
- Vey, N.
- Dreyfus, F.
- Béné, M. C.
- Ifrah, N.
- Bouscary, D.
DOIAbstract
International audienceThe mTORC1 signaling pathway is constitutively activated in almost all acute myelogenous leukemia (AML) patients. We conducted a phase Ib trial combining RAD001 (everolimus), an allosteric inhibitor of mTORC1, and conventional chemotherapy, in AML patients under 65 years of age at first relapse (clinical trial NCT 01074086). Increasing doses of RAD001 from 10-70 mg were administrated orally on days 1 and 7 (d1 and d7) of a 3+7 daunorubicin+cytarabine conventional induction chemotherapy regimen. Twenty-eight patients were enrolled in this trial. The treatment was well tolerated with <10% toxicity, mainly involving the gastrointestinal tract and lungs. In this phase Ib trial, the RAD001 maximum tolerated dose was not rea...
Add to ORKG